The effectiveness of combining hormone therapy and radiotherapy in the treatment of prostate cancer

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 12, 2004, Pages 2469-2477

  Jani, Ashesh B ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Androgen ablation; Hormone therapy; Prostate cancer; Radiotherapy

Indexed keywords

AMINOGLUTETHIMIDE; AMINOTRANSFERASE; BICALUTAMIDE; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; ESTROGEN; FLUTAMIDE; GESTAGEN; GONADORELIN; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; GOSERELIN; HYDROCORTISONE; KETOCONAZOLE; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; PACLITAXEL; SULINDAC SULFONE; VINBLASTINE;

BODY WEIGHT DISORDER; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DATA BASE; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; ERECTILE DYSFUNCTION; FATIGUE; GYNECOMASTIA; HEPATITIS; HOT FLUSH; HUMAN; HYPOTHYROIDISM; IMPOTENCE; KIDNEY DYSFUNCTION; LIBIDO DISORDER; LIVER TOXICITY; OSTEOPOROSIS; PROSTATE CANCER; RASH; REVIEW; SIDE EFFECT; WATER RETENTION; WEIGHT GAIN;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS; COMBINED MODALITY THERAPY; EXPERT TESTIMONY; HUMANS; MALE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 10644259702     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.12.2469     Document Type: Review

References (33)

1. JANI AB, HELLMAN S: Early prostate cancer: clinical decision-making. Lancet (2003) 361(9362):1048-1053.
2. GRONBERG H: Prostate cancer epidemiology. Lancet (2003) 361(9360):859-864.
3. HUGGINS C: Endocrine-induced regression of cancers. Science (1967) 156(778):1050-1054.
4. PROSTATE CANCER TRIALISTS' COLLABORATIVE GROUP: Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet (1995) 346(8970):265-269.
5. PROSTATE CANCER TRIALISTS' COLLABORATIVE GROUP: Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet (2000) 355(9214):1491-1498.
6. PILEPICH MV, WINTER K, JOHN MJ et al.: Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. (2001) 50(5):1243-1252.
7. LAVERDIERE J, GOMEZ JL, CUSAN L et al.: Beneficial effect of combination hormonal therapy admistered prior and following external beam radiation therapy in localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. (1997) 37(2):247-252.
8. LAWTON CA, WINTER K, MURRAY K et al.: Updated results of the Phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int. J. Radiat. Oncol. Biol Phys. (2001) 49 4):937-946.
9. BOLLA M, COLLETTE L, BLANK L et al.: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a Phase III randomised trial. Lancet (2002) 360(9327):103-106.
10. HANKS GE, PAJAK TF, PORTER A et al.: Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J. Clin. Oncol. (2003) 21(21):3972-3978.
11. ROACH M 3rd, DESILVIO M, LAWTON C et al.: Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression:Radiation Therapy Oncology Group 9413. J. Clin. Oncol. (2003) 21 10):1904-1911.
12. JANI AB, KAO J, HELLMAN S: Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma: a complication-adjusted number-needed-to-treat analysis. Cancer (2003) 98(11):2351-2361.
13. D'AMICO AV, SCHULTZ D, LOFFREDO M et al.: Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA (2000) 284(10):1280-1283.
14. JANI AB, BASU A, ABDALLA I et al.: The impact of hormone therapy when combined with external beam radiotherapy for early-stage, intermediate- or high-risk prostate cancer. Am. J. Clin. Oncol.(2003) 26(4):382-385.
15. LEE LN, STOCK RG, STONE NN: Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int. J. Radiat. Oncol. Biol. Phys. (2002) 52(2):444-452.
16. DAMICO AV, WHITTINGTON R, MALKOWICZ SB et al.: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically locaked prostate cancer. JAMA (1998) 280(11):969-974.
17. MERRICK GS, BUTLER WM, GALBREATH RW, LIEF JH, ADAMOVICH E: Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer? BJU Int. (2003) 91(1):23-29.
18. POTTERS L, TORRE T, ASHLEY R, LEIBEL S: Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. J. Clin. Oncol. (2000) 18(6):1187-1192.
19. MARTINEZ A, GALALAE R, GONZALEZ J et al.: No apparent benefit at 5 years ftorn a course of neoadjuvant/concturent androgen deprivation for patients with prostate cancer treated with a high total radiation dose. J. Urol. (2003) 170(6 Pt 1):2296-2301.
20. JANI AB, KAO J, HEIMANN R, HELLMAN S: Hormone therapy adjuvant to external beam radiotherapy for early prostate cancer: a complication-adjusted number-needed to treat (NNT) analysis. Int. J. Radiat. Oncol. Biol. Phys. (In Press).
21. D'AMICO AV, MANOLA J, LOFFREDO M et al.: 6-month androgen suppression plus radiation therapy versus radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA (2004) 292(7):821-827.
22. WIEGEL T, BRESSEL M, CARL UM: Adjuvant radiotherapy following radical prostatectomy - results of 56 patients. Eur. J. Cancer (1995) 31A(1):5-11.
23. TAYLOR N, KELLY JF, KUBAN DA et al.: Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. (2003) 56(3):755-763.
24. DE LA TAILLE, FLAM TA, THIOUNN N et al.: Predictive factors of radiation therapy for patients with prostate specific antigen recurrence after radical prostatectomy. BJU Int. (2002) 90 9): 887-892.
25. KATZ MS, ZELEFSKY MJ, VENKATRAMAN ES, FUKS Z, HUMMER A, LEIBEL SA: Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J. Clin. Oncol. (2003) 21(3):483-489.
26. KING CR, PRESTI JC Jr, GILL H, BROOKS J, HANCOCK SL: Radiotherapy after radical prostatectomy-does transient androgen suppression improve outcomes? Int. J. Radiat. Oncol. Biol. Phys. (2004) 59(2):341-347.
27. SONG DY, THOMPSON TL, RAMAKRISHNAN V et al.: Salvage radiotherapy for rising or persistent PSA after radical prostatectomy. Urology (2002) 60(2):281-287.
28. CORN BW, WINTER K, PILEPICH MV: Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31. Urology (1999) 54(3):495-502.
29. JANI AB, SOKOLOFF M, SHALHAV A, STADLER W: Androgen ablation adjuvant to post-prostatectomy radiotherapy: a complication-adjusted number-needed to treat analysis. Urology (In Press).
30. HOLZBEIERLEIN JM, CASTLE E, THRASHER JB: Complications of androgen deprivation therapy: prevention and treatment. Oncology (2004) 18(3):303-309.
31. JANI AB, ROESKE JC, RASH C: Intensity-modulated radiation therapy for prostate cancer. Clin. Prostate Cancer (2003) 2 2):98-105.
32. JANI AB: Organ motion and IMRT in prostate cancer therapy. Cancer J. (2003) 9(4):244-246.
33. POLLACK A, ZAGARS GK, STARKSCHALL G et al.: Prostate cancer radiation dose response: results of the M. D. Anderson Phase III randomized trial. Int. J. Radiat. Oncol. Biol. Phys. (2002) 53 5):1097-1105.